SPHK1 and acute myeloid leukemia: The involvement of bioactive SLs in AML is a rapidly expanding field, with initial studies exploring SPHK1 as a therapeutic target [137,138,139] and showing decreased ceramide levels associated with increased GCS and SMS activities as indicative of chemoresistance [140].